158 related articles for article (PubMed ID: 10626152)
1. Prognostic factors in multiple myeloma.
Rajkumar SV; Greipp PR
Hematol Oncol Clin North Am; 1999 Dec; 13(6):1295-314, xi. PubMed ID: 10626152
[TBL] [Abstract][Full Text] [Related]
2. Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma.
Rajkumar SV; Fonseca R; Lacy MQ; Witzig TE; Therneau TM; Kyle RA; Litzow MR; Gertz MA; Greipp PR
J Clin Oncol; 1999 May; 17(5):1551-7. PubMed ID: 10334543
[TBL] [Abstract][Full Text] [Related]
3. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
4. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.
Hose D; Rème T; Hielscher T; Moreaux J; Messner T; Seckinger A; Benner A; Shaughnessy JD; Barlogie B; Zhou Y; Hillengass J; Bertsch U; Neben K; Möhler T; Rossi JF; Jauch A; Klein B; Goldschmidt H
Haematologica; 2011 Jan; 96(1):87-95. PubMed ID: 20884712
[TBL] [Abstract][Full Text] [Related]
5. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma.
Greipp PR; Lust JA; O'Fallon WM; Katzmann JA; Witzig TE; Kyle RA
Blood; 1993 Jun; 81(12):3382-7. PubMed ID: 8507875
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological features of plasmablastic multiple myeloma: a population-based cohort.
Møller HE; Preiss BS; Pedersen P; Kristensen IB; Hansen CT; Frederiksen M; Abildgaard N; Møller MB
APMIS; 2015 Aug; 123(8):652-8. PubMed ID: 26152595
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of plasma cell morphology in multiple myeloma.
Carter A; Hocherman I; Linn S; Cohen Y; Tatarsky I
Cancer; 1987 Sep; 60(5):1060-5. PubMed ID: 3607725
[TBL] [Abstract][Full Text] [Related]
8. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma.
Königsberg R; Zojer N; Ackermann J; Krömer E; Kittler H; Fritz E; Kaufmann H; Nösslinger T; Riedl L; Gisslinger H; Jäger U; Simonitsch I; Heinz R; Ludwig H; Huber H; Drach J
J Clin Oncol; 2000 Feb; 18(4):804-12. PubMed ID: 10673522
[TBL] [Abstract][Full Text] [Related]
9. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in multiple myeloma: practicability for clinical practice and future perspectives.
Haferlach T; Löffler H
Leukemia; 1997 Dec; 11 Suppl 5():S5-9. PubMed ID: 9436931
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of vascular endothelial growth factor immunoexpression in the context of adverse standard prognostic factors in multiple myeloma.
Ribas C; Colleoni GW; Silva MR; Carregoza MJ; Bordin JO
Eur J Haematol; 2004 Nov; 73(5):311-7. PubMed ID: 15458509
[TBL] [Abstract][Full Text] [Related]
12. Increased copy number of the interleukin-6 receptor gene is associated with adverse survival in multiple myeloma patients treated with autologous stem cell transplantation.
Kim SY; Min HJ; Park HK; Oh B; Kim TY; She CJ; Hwang SM; Kim M; Kim HK; Kim I; Yoon SS; Park S; Kim BK; Lee JH; Lee DS;
Biol Blood Marrow Transplant; 2011 Jun; 17(6):810-20. PubMed ID: 21220034
[TBL] [Abstract][Full Text] [Related]
13. Circulating plasma cells in newly diagnosed symptomatic multiple myeloma as a possible prognostic marker for patients with standard-risk cytogenetics.
Vagnoni D; Travaglini F; Pezzoni V; Ruggieri M; Bigazzi C; Dalsass A; Mestichelli F; Troiani E; Falcioni S; Mazzotta S; Natale A; Angelini M; Ferretti S; Angelini S; Galieni P
Br J Haematol; 2015 Aug; 170(4):523-31. PubMed ID: 26010293
[TBL] [Abstract][Full Text] [Related]
14. Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I.
Gastinne T; Leleu X; Duhamel A; Moreau AS; Franck G; Andrieux J; Lai JL; Coiteux V; Yakoub-Agha I; Bauters F; Harousseau JL; Zandecki M; Facon T;
Eur J Haematol; 2007 Oct; 79(4):297-304. PubMed ID: 17692103
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of cytogenetic aberrations in patients with multiple myeloma or monoclonal gammopathy of unknown significance.
Schilling G; Dierlamm J; Hossfeld DK
Hematol Oncol; 2005; 23(3-4):102-7. PubMed ID: 16342296
[TBL] [Abstract][Full Text] [Related]
16. Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma.
Greipp PR; Katzmann JA; O'Fallon WM; Kyle RA
Blood; 1988 Jul; 72(1):219-23. PubMed ID: 3291982
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of plasma cell morphology in multiple myeloma.
Paule B; Quillard J; Bisson M; Kahn MF; Massias P
Nouv Rev Fr Hematol (1978); 1988; 30(4):209-12. PubMed ID: 3194186
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic value of the ratio of bone marrow plasma cells in multiple myeloma].
Pasqualetti P; Colantonio D; Casale R
Minerva Med; 1990 Mar; 81(3):129-33. PubMed ID: 2320280
[TBL] [Abstract][Full Text] [Related]
19. Extramedullary disease in multiple myeloma.
Bansal R; Rakshit S; Kumar S
Blood Cancer J; 2021 Sep; 11(9):161. PubMed ID: 34588423
[TBL] [Abstract][Full Text] [Related]
20. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study.
Fonseca R; Harrington D; Oken MM; Dewald GW; Bailey RJ; Van Wier SA; Henderson KJ; Blood EA; Rajkumar SV; Kay NE; Van Ness B; Greipp PR
Cancer Res; 2002 Feb; 62(3):715-20. PubMed ID: 11830525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
